BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 16899362)

  • 1. Toxicity profile of the immunomodulatory thalidomide analogue, lenalidomide: phase I clinical trial of three dosing schedules in patients with solid malignancies.
    Sharma RA; Steward WP; Daines CA; Knight RD; O'Byrne KJ; Dalgleish AG
    Eur J Cancer; 2006 Sep; 42(14):2318-25. PubMed ID: 16899362
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I trial of pomalidomide given for patients with advanced solid tumors.
    Cooney MM; Nock C; Bokar J; Krishnamurthi S; Gibbons J; Rodal MB; Ness A; Remick SC; Dreicer R; Dowlati A
    Cancer Chemother Pharmacol; 2012 Nov; 70(5):755-61. PubMed ID: 22875080
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II study of lenalidomide in patients with metastatic renal cell carcinoma.
    Choueiri TK; Dreicer R; Rini BI; Elson P; Garcia JA; Thakkar SG; Baz RC; Mekhail TM; Jinks HA; Bukowski RM
    Cancer; 2006 Dec; 107(11):2609-16. PubMed ID: 17075879
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A pilot safety study of lenalidomide and radiotherapy for patients with newly diagnosed glioblastoma multiforme.
    Drappatz J; Wong ET; Schiff D; Kesari S; Batchelor TT; Doherty L; Lafrankie DC; Ramakrishna N; Weiss S; Smith ST; Ciampa A; Zimmerman J; Ostrowsky L; David K; Norden A; Barron L; Sceppa C; Black PM; Wen PY
    Int J Radiat Oncol Biol Phys; 2009 Jan; 73(1):222-7. PubMed ID: 18513880
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lenalidomide in the treatment of multiple myeloma: a review.
    Armoiry X; Aulagner G; Facon T
    J Clin Pharm Ther; 2008 Jun; 33(3):219-26. PubMed ID: 18452408
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of lenalidomide (Revlimid) in recurrent ovarian and primary peritoneal carcinoma.
    Zhang MM; Chan JK; Husain A; Guo HY; Teng NN
    Gynecol Oncol; 2007 Apr; 105(1):194-8. PubMed ID: 17257661
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia.
    Gimsing P; Hansen M; Knudsen LM; Knoblauch P; Christensen IJ; Ooi CE; Buhl-Jensen P
    Eur J Haematol; 2008 Sep; 81(3):170-6. PubMed ID: 18510700
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lenalidomide therapy for metastatic renal cell carcinoma.
    Amato RJ; Hernandez-McClain J; Saxena S; Khan M
    Am J Clin Oncol; 2008 Jun; 31(3):244-9. PubMed ID: 18525302
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma.
    Habermann TM; Lossos IS; Justice G; Vose JM; Wiernik PH; McBride K; Wride K; Ervin-Haynes A; Takeshita K; Pietronigro D; Zeldis JB; Tuscano JM
    Br J Haematol; 2009 May; 145(3):344-9. PubMed ID: 19245430
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II trial of thalidomide and cyclophosphamide in patients with recurrent or refractory pediatric malignancies.
    Gilheeney SW; Lyden DC; Sgouros S; Antunes N; Gerald W; Kramer K; Lis E; Meyers P; Rosen N; Thaler HT; Trippett T; Wexler L; Dunkel IJ
    Pediatr Blood Cancer; 2007 Sep; 49(3):261-5. PubMed ID: 16972243
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I trial of lenalidomide in patients with recurrent primary central nervous system tumors.
    Fine HA; Kim L; Albert PS; Duic JP; Ma H; Zhang W; Tohnya T; Figg WD; Royce C
    Clin Cancer Res; 2007 Dec; 13(23):7101-6. PubMed ID: 18056189
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II trial of dacarbazine and thalidomide for the treatment of metastatic melanoma.
    Ott PA; Chang JL; Oratz R; Jones A; Farrell K; Muggia F; Pavlick AC
    Chemotherapy; 2009; 55(4):221-7. PubMed ID: 19451711
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma.
    Wiernik PH; Lossos IS; Tuscano JM; Justice G; Vose JM; Cole CE; Lam W; McBride K; Wride K; Pietronigro D; Takeshita K; Ervin-Haynes A; Zeldis JB; Habermann TM
    J Clin Oncol; 2008 Oct; 26(30):4952-7. PubMed ID: 18606983
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Results of a multicenter, randomized, double-blind, dose-evaluating phase 2/3 study of lenalidomide in the treatment of metastatic malignant melanoma.
    Glaspy J; Atkins MB; Richards JM; Agarwala SS; O'Day S; Knight RD; Jungnelius JU; Bedikian AY
    Cancer; 2009 Nov; 115(22):5228-36. PubMed ID: 19728370
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined bendamustine, prednisolone and thalidomide for refractory or relapsed multiple myeloma after autologous stem-cell transplantation or conventional chemotherapy: results of a Phase I clinical trial.
    Pönisch W; Rozanski M; Goldschmidt H; Hoffmann FA; Boldt T; Schwarzer A; Ritter U; Rohrberg R; Schwalbe E; Uhlig J; Zehrfeld T; Schirmer V; Haas A; Kreibich U; Niederwieser D;
    Br J Haematol; 2008 Oct; 143(2):191-200. PubMed ID: 18752593
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I study to determine the safety and pharmacokinetics of oral administration of TAS-102 in patients with solid tumors.
    Hong DS; Abbruzzese JL; Bogaard K; Lassere Y; Fukushima M; Mita A; Kuwata K; Hoff PM
    Cancer; 2006 Sep; 107(6):1383-90. PubMed ID: 16902987
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies.
    Mita MM; Mita AC; Chu QS; Rowinsky EK; Fetterly GJ; Goldston M; Patnaik A; Mathews L; Ricart AD; Mays T; Knowles H; Rivera VM; Kreisberg J; Bedrosian CL; Tolcher AW
    J Clin Oncol; 2008 Jan; 26(3):361-7. PubMed ID: 18202410
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The potential of immunomodulatory drugs in the treatment of solid tumors.
    Dalgleish A; Galustian C
    Future Oncol; 2010 Sep; 6(9):1479-84. PubMed ID: 20919830
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA--Italian Multiple Myeloma Network.
    Palumbo A; Falco P; Corradini P; Falcone A; Di Raimondo F; Giuliani N; Crippa C; Ciccone G; Omedè P; Ambrosini MT; Gay F; Bringhen S; Musto P; Foà R; Knight R; Zeldis JB; Boccadoro M; Petrucci MT;
    J Clin Oncol; 2007 Oct; 25(28):4459-65. PubMed ID: 17785703
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I clinical and pharmacokinetic study of kahalalide F administered weekly as a 1-hour infusion to patients with advanced solid tumors.
    Pardo B; Paz-Ares L; Tabernero J; Ciruelos E; García M; Salazar R; López A; Blanco M; Nieto A; Jimeno J; Izquierdo MA; Trigo JM
    Clin Cancer Res; 2008 Feb; 14(4):1116-23. PubMed ID: 18281545
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.